We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
We expect Amgen, Inc. (AMGN - Free Report) to beat expectations when it reports third-quarter 2020 results on Oct 28, after market close. In the last reported quarter, the company delivered an earnings surprise of 11.55%.
The large biotech’s performance has been pretty impressive, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 8.58%, on average.
Amgen’s stock has declined 5.4% this year so far compared with an decrease of 4.1% for the industry.
Factors to Consider
Due to the COVID-19 pandemic, interruptions to physician-patient interactions (due to decline in patient visits to doctors) led to delays in diagnosis and treatment of several of Amgen’s drugs like Prolia, Xgeva, Kyprolis in the second quarter. However, the negative impact from COVID-19 is likely to have been much less in the third quarter. It remains to be seen if sales of these drugs improved in the third quarter.
However, higher demand is likely to have benefited sales of Blincyto and Parsabiv in the third quarter. Meanwhile, COVID-19 may have benefited sales of Otezla as it provides a convenient oral formulation and is conducive to telemedicine. The Zacks Consensus Estimate for Otezla is $583 million in the quarter.
Please note that Otezla was purchased by Amgen from Celgene in November 2019 as the latter had to divest the drug in order to complete its merger with Bristol-Myers (BMY - Free Report) .
The respective Zacks Consensus Estimate for Prolia, Xgeva, Blincyto, Parsabiv, Repatha and Kyprolis sales is pegged at $681 million, $475 million, $94 million, $197 million, $214 million and $270 million.
Sales of new drug, Evenity are expected to have been soft in the third quarter as the first half of 2020 benefited from larger shipments to Amgen’s Japan-based partner, Astellas. The Zacks Consensus Estimate for Evenity is $104 million.
Also, increasing branded and generic competition for its legacy products like Enbrel, Aranesp, Epogen, Neupogen, Neulasta and Sensipar are likely to have hurt the top line.
Amgen’s biosimilars drugs may have once again been an important contributor to top-line growth driven by the launches of Kanjinti (Amgen’s biosimilar of Roche’s (RHHBY - Free Report) Herceptin) and Mvasi (biosimilar of Roche’s Avastin) in the United States in 2019. However, it remains to be seen if increasing competitive pressure on Kanjinti and Mvasi because of the launch of competing biosimilar products impacted sales when the company reports third-quarter results.
Operating expenses are expected to have been meaningfully higher in the third quarter due to investments in pipeline due to acceleration in clinical trial and lab activity and launch preparation for its late-stage pipeline products.
Earnings Whispers
Our proven model predicts an earnings beat for Amgen in the soon-to-be-reported quarter because it has the right combination of the two key ingredients. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise.
Earnings ESP: Amgen’s Earnings ESP is +0.20% as the Zacks Consensus Estimate of $3.74 is lower than the Most Accurate Estimate of $3.75. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here is a large biotech stock that you may also want to consider, as our model shows that it has the right combination of elements to post an earnings beat this season.
Incyte (INCY - Free Report) has an Earnings ESP of +5.35% and a Zacks Rank #3.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Shutterstock
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
We expect Amgen, Inc. (AMGN - Free Report) to beat expectations when it reports third-quarter 2020 results on Oct 28, after market close. In the last reported quarter, the company delivered an earnings surprise of 11.55%.
The large biotech’s performance has been pretty impressive, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 8.58%, on average.
Amgen Inc. Price and EPS Surprise
Amgen Inc. price-eps-surprise | Amgen Inc. Quote
Amgen’s stock has declined 5.4% this year so far compared with an decrease of 4.1% for the industry.
Factors to Consider
Due to the COVID-19 pandemic, interruptions to physician-patient interactions (due to decline in patient visits to doctors) led to delays in diagnosis and treatment of several of Amgen’s drugs like Prolia, Xgeva, Kyprolis in the second quarter. However, the negative impact from COVID-19 is likely to have been much less in the third quarter. It remains to be seen if sales of these drugs improved in the third quarter.
However, higher demand is likely to have benefited sales of Blincyto and Parsabiv in the third quarter. Meanwhile, COVID-19 may have benefited sales of Otezla as it provides a convenient oral formulation and is conducive to telemedicine. The Zacks Consensus Estimate for Otezla is $583 million in the quarter.
Please note that Otezla was purchased by Amgen from Celgene in November 2019 as the latter had to divest the drug in order to complete its merger with Bristol-Myers (BMY - Free Report) .
The respective Zacks Consensus Estimate for Prolia, Xgeva, Blincyto, Parsabiv, Repatha and Kyprolis sales is pegged at $681 million, $475 million, $94 million, $197 million, $214 million and $270 million.
Sales of new drug, Evenity are expected to have been soft in the third quarter as the first half of 2020 benefited from larger shipments to Amgen’s Japan-based partner, Astellas. The Zacks Consensus Estimate for Evenity is $104 million.
Also, increasing branded and generic competition for its legacy products like Enbrel, Aranesp, Epogen, Neupogen, Neulasta and Sensipar are likely to have hurt the top line.
Amgen’s biosimilars drugs may have once again been an important contributor to top-line growth driven by the launches of Kanjinti (Amgen’s biosimilar of Roche’s (RHHBY - Free Report) Herceptin) and Mvasi (biosimilar of Roche’s Avastin) in the United States in 2019. However, it remains to be seen if increasing competitive pressure on Kanjinti and Mvasi because of the launch of competing biosimilar products impacted sales when the company reports third-quarter results.
Operating expenses are expected to have been meaningfully higher in the third quarter due to investments in pipeline due to acceleration in clinical trial and lab activity and launch preparation for its late-stage pipeline products.
Earnings Whispers
Our proven model predicts an earnings beat for Amgen in the soon-to-be-reported quarter because it has the right combination of the two key ingredients. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise.
Earnings ESP: Amgen’s Earnings ESP is +0.20% as the Zacks Consensus Estimate of $3.74 is lower than the Most Accurate Estimate of $3.75. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Amgen has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Another Stock to Consider
Here is a large biotech stock that you may also want to consider, as our model shows that it has the right combination of elements to post an earnings beat this season.
Incyte (INCY - Free Report) has an Earnings ESP of +5.35% and a Zacks Rank #3.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>